• Robert E Fowles.
• Cardiology Division, LDS Hospital and the Salt Lake Clinic, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, UT, USA. slrfowle@ihc.com
• J Pain Palliat Care Pharmacother. 2003 Jan 1; 17 (2): 27-50.

AbstractThe newly developed nonsteroidal antiinflammatory drugs (NSAIDs) that selectively inhibit cyclooxygenase-2 (COX-2), are effective against pain and inflammation and appear to have less gastrointestinal toxicity than conventional NSAIDs. Their COX-2 selectivity, however, has raised concerns regarding their cardiovascular safety, since they do not inhibit COX-1, the isoform of the enzyme that is active in thrombosis and vasoconstriction. At this point there is no conclusive evidence that COX-2 inhibitors cause ischemic vascular events, because retrospective post hoc analyses conflict one another, and no specific randomized trials have yet been done. Renal effects, edema and hypertension appear to be similar between conventional NSAIDs and COX-2-selective inhibitors. Aspirin is still required for patients with cardiovascular risk who are prescribed a COX-2-selective inhibitor.

17 keywords...

hide…